Characteristics and care of chronic hepatitis C treated with direct-acting antivirals in migrants

被引:0
|
作者
Doffoel, Michel [1 ]
Ernwein, Florence [1 ]
Chaffraix, Frederic [1 ]
Haumesser, Lucile [2 ]
Tripon, Simona [1 ]
Bader, Robert [3 ]
Lang, Jean-Philippe [1 ]
Lang, Anais [1 ]
Paya, Dominique [4 ]
Royant, Maude [1 ]
Velay-Rusch, Aurelie [5 ]
Tebacher, Martine [6 ]
Meyer, Nicolas [2 ]
Habersetzer, Francois [7 ]
Baumert, Thomas [8 ]
机构
[1] Hop Univ, Nouvel Hop Civil, Serv Expert Lutte Hepatites Virales Dalsace SELVH, Pole Hepatodigestif, F-67091 Strasbourg, France
[2] Hop Univ, Grp Methode Rech Clin, Pole Sante Publ Travail, Strasbourg, France
[3] Hop Emile Muller, Grp Hosp Reg Mulhouse Sud Alsace GHRMSA, Pole Pathol Digest & Urol, Serv Hepatogastroenterol & Med Trop, Mulhouse, France
[4] Hop Univ, Pharm, Strasbourg, France
[5] Hop Univ, Lab Virol, Strasbourg, France
[6] Hop Univ, Ctr Reg Pharmacovigilance Grand Est, Strasbourg, France
[7] Hop Univ, Serv Hepatogastroenterol, Pole Hepatodigestif, Strasbourg, France
[8] Univ Strasbourg, INSERM, U1110, Inst Rech Malad Virales & Hepat, Strasbourg, France
关键词
direct-acting antivirals; hepatitis C; migrants; multidisciplinary team meetings; VIRUS-INFECTION; PREVALENCE;
D O I
10.1097/MEG.0000000000002333
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims Hepatitis C is poorly documented in migrants. The published studies mainly concern the screening in this population and are limited to some countries in Europe and North America. This study aimed to evaluate the characteristics and care of chronic hepatitis C in this population compared to the nonmigrant population, in the era of direct-acting antivirals (DAAs). Method We performed a retrospective analysis based on data presented at the multidisciplinary team meetings of our tertiary care center between 2015 and 2019. Results We included 277 migrant- and 1390 nonmigrant patients mono-infected with hepatitis C virus (HCV) and treated with DAAs. The majority of the migrants were from Eastern European countries. In multivariable analysis, BMI classes associated with more obesity (OR = 1.84; 95% CI, 1.37-2.49; P < 0.001) and therapeutic patient education (OR = 3.91; 95% CI, 2.38-6.49; P < 0.001) were positively associated with migrant status, whereas age (OR = 0.92; 95% CI, 0.90-0.94; P < 0.001), female gender (OR = 0.46; 95% CI, 0.28-0.74; P = 0.002), modes of contamination with less drug use, transfusion history or nosocomial risk, as well more unknown mode (OR = 0.70; 95% CI, 0.50-0.96; P = 0.031), alcohol consumption (OR = 0.48; 95% CI, 0.29-0.73; P = 0.001), types of structures with less care in a general hospital or health network of general practitioners and more care in a university hospital or primary addictology center (OR = 0.78; 95% CI, 0.60-0.99; P = 0.046) and opioid substitution therapy (OR = 0.25; 95% CI, 0.08-0.68; P = 0.008) were negatively associated with migrant status. The substained virologic response 12 was close to 97% in both groups. Conclusion Despite multiple differences in characteristics and therapeutic care between the two populations, the chances of healing hepatitis C were the same among migrant- compared with nonmigrant patients.
引用
收藏
页码:664 / 670
页数:7
相关论文
共 50 条
  • [21] Current therapy for chronic hepatitis C: The role of direct-acting antivirals
    Li, Guangdi
    De Clercq, Erik
    ANTIVIRAL RESEARCH, 2017, 142 : 83 - 122
  • [22] Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance
    Miguel Jiménez-Pérez
    Rocío González-Grande
    Pilar Espa?a Contreras
    Isabel Pinazo Martínez
    Jesús de la Cruz Lombardo
    Raúl Olmedo Martín
    World Journal of Gastroenterology, 2016, 22 (29) : 6573 - 6581
  • [23] Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C
    Mondelli, Mario U.
    GASTROENTEROLOGY, 2015, 149 (01) : 25 - 28
  • [24] Cost-effectiveness of direct-acting antivirals for chronic hepatitis C
    Gaby Sroczynski
    Uwe Siebert
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 : 572 - 574
  • [25] Changing Cascade of Care for Hepatitis C in the Era of Direct-Acting Antivirals
    Chhatwal, Jag
    Chen, Qiushi
    Bethea, Emily
    Ayer, Turgay
    Zhuo, Yueran
    Hur, Chin
    Spaulding, Anne
    Kanwal, Fasiha
    HEPATOLOGY, 2018, 68 : 918A - 919A
  • [26] Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
    Ioanna Aggeletopoulou
    Christos Konstantakis
    Spilios Manolakopoulos
    Christos Triantos
    World Journal of Gastroenterology, 2017, (24) : 4317 - 4323
  • [27] Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting
    Gayam, Vijay
    Khalid, Mazin
    Mandal, Amrendra Kumar
    Hussain, Muhammad Rajib
    Mukhtar, Osama
    Gill, Arshpal
    Garlapati, Pavani
    Shrestha, Binav
    Guss, Debra
    Sherigar, Jagannath
    Mansour, Mohammed
    Mohanty, Smruti
    GASTROENTEROLOGY RESEARCH, 2018, 11 (02) : 130 - 137
  • [28] Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
    Aggeletopoulou, Ioanna
    Konstantakis, Christos
    Manolakopoulos, Spilios
    Triantos, Christos
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (24) : 4317 - 4323
  • [29] VIRAL HEPATITIS Cost-effectiveness of direct-acting antivirals for chronic hepatitis C
    Sroczynski, Gaby
    Siebert, Uwe
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (10) : 572 - 574
  • [30] Therapy completion of direct-acting antivirals for hepatitis C
    Machado, Marina A. A.
    Moura, Cristiano S.
    Klein, Marina
    Carleton, Bruce
    Winthrop, Kevin
    Abrahamowicz, Michal
    Feld, Jordan
    Curtis, Jeffrey R.
    Bernatsky, Sasha
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 498 - 499